Tetrahydroisoquinoline derivative serving as general-KRAS inhibitor as well as preparation method and application of tetrahydroisoquinoline derivative
Patent Information
- Application Number
- CN202380026513.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-09
- Filing Date
- 2023-03-08
- Publication Date
- 2024-11-08
AI Technical Summary
It is difficult to develop effective pan-KRAS inhibitors with existing technology, especially for KRAS G12D mutants, and the efficacy of existing inhibitors is limited by the narrow window of targeting KRAS downstream signaling pathways and the impact of compensation mechanisms, resulting in oral safety Safety and effectiveness are difficult to meet clinical needs.
Provided is a tetrahydroisoquinoline derivative compound that has the activity of inhibiting KRAS-effector protein interaction and serves as a pan-KRAS inhibitor for the treatment of KRAS mutation-related tumors, including intestinal cancer, lung cancer, pancreatic cancer, etc. Through specific structural design, this compound can effectively inhibit the activity of KRAS and bypass the limitations of existing targeted downstream signaling pathways.
It achieves effective inhibition of KRAS mutants, significantly improves the therapeutic efficacy of KRAS G12D mutants, provides an oral safe and effective treatment option, and enhances the therapeutic potential for a variety of tumors.
Smart Images

Figure CN118922418A_ABST
Abstract
Description
A class of tetrahydroisoquinoline derivatives as pan-KRAS inhibitors and their preparation method and application Technical Field
[0001] The present application relates to a class of tetrahydroisoquinoline derivatives, a preparation method thereof, a pharmaceutical composition containing these compounds or their salts, and their medical use as pan-KRAS inhibitors in the treatment of various tumors. Background Art
[0002] RAS was the first human oncogene discovered and is one of the most commonly mutated genes in tumors. RAS mutations are found in approximately 30% of tumors. Combined with mutations in RAS regulatory factors and upstream and downstream signaling pathways, these mutations cover nearly all tumors. The KRAS gene (Kirsten rat sarcoma viral oncogene homolog) is a key member of the RAS gene family. The protein encoded by the KRAS gene is a GDP / GTP-binding protein, a small GTPase enzyme that belongs to the superprotein family. The KRAS protein has 188 amino acids and a molecular weight of 21.6 kDa. It is located on the inner side of the cell membrane and is attached to the cell membrane via a farnesyl modification gene. KRAS is in an activated state when bound to GTP (KRAS-GTP) and in a closed state (or inactive state) when bound to GDP (KRAS-GDP). Subsequently, the GTPase-activating protein (GAP) hydrolyzes the GTP bound to KRAS-GTP to GDP, promoting the formation of the closed state of KRAS-GDP, thereby inactivating KRAS. The KRAS protein acts as a "switch" between the KRAS-GTP activated state and the KRAS-GDP inactive state (off state). In the activated state, it activates downstream signaling pathways, including the MAPK signaling pathway, the PI3K signaling pathway, and the Ral-GDS signaling pathway. The RAS protein switch controls its downstream signaling pathways, thereby promoting cell survival, proliferation, and cytokine release, playing a vital role in life processes such as cell proliferation, differentiation, and apoptosis. KRAS can also be briefly activated by growth factors (such as EGFR). The activated KRAS can activate downstream signaling pathways such as the PI3K-AKT-mTOR signaling pathway that controls cell generation, and the RAS-RAF-MEK-ERK signaling pathway that controls cell proliferation. Mutated KRAS will continue to be activated even in the absence of kinase activation such as EGFR, leading to continued cell proliferation and ultimately cancer.
[0003] KRAS mutations are highly expressed in a variety of tumors, with the most common being lung cancer, intestinal cancer, pancreatic cancer, colon cancer, small intestinal cancer, and bile duct cancer. Structural studies have shown that most KRAS mutations interfere with KRAS's ability to hydrolyze GTP, ultimately leading to persistent KRAS activation and an inability to effectively regulate cellular signaling, thereby promoting tumor development, progression, and metastasis.
[0004] Mutations at amino acid position 12 (G12) account for approximately 80% of KRAS mutations, while G12C mutations account for approximately 14% of all G12 mutations. In recent years, researchers have developed a series of covalent inhibitors for the KRAS G12C mutation, but developing inhibitors for the KRAS G12D mutation has been a significant challenge.
[0005] Currently, no method for covalent binding to aspartic acid has been developed. The difficulty in directly inhibiting the KRAS G12D mutant lies not only in the smooth surface of the protein encoded by KRAS and the lack of binding sites, but also in the very strong binding affinity between KRAS and GTP / GDP, and the high concentration of intracellular GTP / GDP, which makes it impossible to develop competitive inhibitors for GTP. Not only is the membrane localization of KRAS regulated by enzymes such as farnesyltransferases, but the therapeutic window for targeting KRAS downstream signaling molecules (effector proteins) and inhibiting the wild-type signaling pathway required for growth is narrow. Moreover, due to compensatory mechanisms, it is impossible to completely and effectively inhibit the downstream signaling of KRAS mutants, thus greatly limiting the efficacy of kinase inhibitors developed for effector proteins against KRAS mutations.
[0006] In summary, there is still a great unmet clinical need for the development of pan-KRAS inhibitors that are safe and effective orally.
[0007] Summary of the Invention
[0008] The purpose of the present invention is to provide a pan-KRAS inhibitor that is safe and effective for oral administration, in particular an inhibitor for the treatment of tumors such as colorectal cancer, lung cancer, pancreatic cancer, bile duct cancer, and gastric cancer.
[0009] The first aspect of the present invention provides a compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof,
[0010] Wherein, the carbon atom marked with * is a chiral center, and each chiral center can be optionally in R configuration or S configuration;
[0011] R1 is selected from the group consisting of:
[0012] wherein A, B, C and D are each independently selected from the group consisting of CH, CF, C(OMe), CMe or N;
[0013] Each R'1 is independently selected from the group consisting of halogen, OH, OCH2CH2NR a R b , SH, NH2, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkylhydroxyl, S (C1-C6 alkyl), allyl, vinyl, aryl (including monocyclic or condensed ring aryl), heteroaryl (including monocyclic or condensed ring heteroaryl), COR a 、CONH2、CONR a R b 、NHR a , 3-7 membered cycloalkyl, 3-7 membered heterocyclyl, (C1-C4 alkyl) 3-7 membered heterocyclyl; wherein, when A, B, C or D is CH, each R'1 may be optionally located on A, B, C or D, and in this case, the H atom on A, B, C or D is replaced by R'1;
[0014] R a Selected from the group consisting of H, C1-C5 alkyl;
[0015] R b Selected from the group consisting of H, C1-C5 alkyl, or C1-C5 haloalkyl;
[0016] m is 0, 1, 2, 3, 4 or 5;
[0017] R2 is selected from the following group: halogen, OH, NH2, NHR a , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, allyl, vinyl, OCD3, OR c , 3-7 membered cycloalkyl, 3-7 membered heterocyclic group, (C1-C4 alkyl) 3-7 membered heterocyclic group, SR c , B(OH)2, or a heterocycle selected from the group consisting of: Preferably, R2 is selected from the group consisting of OMe, OCD3;
[0018] R c is a C1-C6 alkyl group or an allyl group;
[0019] L is selected from the group consisting of a single bond, O, S, NH, N(C1-C6 alkyl), CH2, CF2;
[0020] Q is selected from the group consisting of a single bond, (CH2) p ; wherein p is 1, 2, 3 or 4;
[0021] R3 is selected from the following group: H,
[0022] Each R3' can be independently located at any position on the ring and is independently selected from the following group: halogen, OH, SH, NH2, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkylhydroxy, S(C1-C6 alkyl), allyl, vinyl, aryl (including monocyclic or condensed ring aryl), heteroaryl (including monocyclic or condensed ring heteroaryl), piperidinyl, morpholinyl; n is 0, 1, 2 or 3;
[0023] X is selected from the group consisting of O, N, NH, S, CH, CH2, CF2, CFH, NR a ;
[0024] Y is selected from the group consisting of NH, CH, CO, CH2, CF2, CR a , OR a 、S(C1-C6 alkyl), C(NR a R b ), C(aryl), C(heteroaryl), C(3-8 membered cycloalkyl), C(3-8 membered heterocyclyl);
[0025] Z, E and F are each independently selected from the group consisting of O, N, NH, S, CH, CH2, CF2, CFH, NR a ;
[0026] R4 is selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylhydroxy, C1-C6 alkoxy, C2-C6 acyl, allyl, cycloalkyl, heterocyclyl, propargyl, C(O)NH2, CH2(aryl), CH2(heteroaryl), C(O)NH(C1-C6 alkyl), C(O)NH(aryl), C(O)NH(heteroaryl), C(O)NHCH2(aryl), C(O)NHCH2(heteroaryl), C(S)NH2, C(S)NH(C1-C6 alkyl), C(S)NH(aryl), C(S)NH(heteroaryl), C(S)NHCH2(aryl), C(S)NHCH2(heteroaryl), aryl, heteroaryl;
[0027] R5 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, and cycloalkyl; preferably, R5 is selected from the group consisting of methyl, fluoromethyl, ethyl, fluoroethyl, deuterated methyl, isopropyl, and cyclopropyl;
[0028] R6 or R7 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C2-C6 alkenyl, CH2O(C1-C5 alkyl);
[0029] When R5 is H, R3 is selected from the following group:
[0030] In the above formulas, unless otherwise specified, the aryl group is C6-C 14 Aryl, heterocyclic group is 3-12 membered heterocyclic group, heteroaryl is 5-14 membered heteroaryl (such as 5-6 membered heteroaryl or benzo 5-6 membered heteroaryl), cycloalkyl is C3-C 12 Cycloalkyl (e.g., C3-C6 cycloalkyl or C3-C8 cycloalkyl); the heterocyclic group or heteroaryl group includes 1-3 heteroatoms selected from the group consisting of N, S, O, P, or B; and unless otherwise specified, the vinyl, allyl, propargyl, aryl, heteroaryl, cycloalkyl, and heterocyclic group may optionally have 1-3 substituents selected from the group consisting of halogen, deuterium atom, and C1-C6 alkyl;
[0031] The heterocyclic group includes saturated or partially unsaturated nitrogen, oxygen or sulfur heterocycles;
[0032] It is a single bond or a double bond.
[0033] In another preferred embodiment, L is selected from the following group: O, S, NH, CF2; Q is selected from the following group: (CH2) p ; where p is 1, 2 or 3.
[0034] In another preferred embodiment, R4 is selected from the following group: C(O)NH(C1-C6 alkyl), C(O)NH(aryl), C(O)NH(heteroaryl), C(O)NHCH2(aryl), C(O)NHCH2(heteroaryl), C(S)NH2, C(S)NH(C1-C6 alkyl), C(S)NH(aryl), C(S)NH(heteroaryl), C(S)NHCH2(aryl), C(S)NHCH2(heteroaryl).
[0035] In another preferred embodiment, R2 is selected from the following group: C1-C6 alkoxy, C1-C6 haloalkoxy, OCD3,
[0036] R5 is selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, and cycloalkyl; preferably, R5 is selected from the group consisting of methyl, fluoromethyl, ethyl, fluoroethyl, deuterated methyl, isopropyl, and cyclopropyl;
[0037] R6 or R7 are each independently selected from the group consisting of hydrogen, deuterium, halogen, and C1-C6 alkyl.
[0038] In another preferred embodiment, the R1 is selected from the following group:
[0039] In another preferred embodiment, the R3 is selected from the following group:
[0040] wherein each R3′ is independently selected from the group consisting of halogen, OH, SH, NH2, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkylhydroxy, S(C1-C6 alkyl), allyl, vinyl, aryl (including monocyclic or condensed ring aryl), heteroaryl (including monocyclic or condensed ring heteroaryl), piperidinyl, and morpholinyl;
[0041] X is selected from the group consisting of O, N, NH, S, CH, CH2, CF2, CFH, NR a ;
[0042] Y is selected from the group consisting of NH, CH, CO, CH2, CF2, CR a , OR a 、S(C1-C6 alkyl), C(NR a R b ), C(aryl), C(heteroaryl), C(3-8 membered cycloalkyl), C(3-8 membered heterocyclyl);
[0043] Z is selected from the following group: O, N, NH, S, CH, CH2, CF2, CFH, NR a ;
[0044] E and F are each independently selected from the group consisting of O, N, NH or S.
[0045] In another preferred embodiment, the R3 is selected from the following group:
[0046] Or the R3 is wherein one of X and Z is selected from the group consisting of O, S, NH, and CH2; and the other is selected from the group consisting of CH and N;
[0047] Y is selected from the group consisting of NH, CH, CO, CH2, CF2, CR a , OR a 、S(C1-C6 alkyl), C(NR a R b ), C(aryl), C(heteroaryl), or a group selected from the group consisting of:
[0048] In another preferred embodiment, the compound of formula I has a structure as shown in the following formula (II), (III), (IV) or (IV-A):
[0049] in:
[0050] R2 is selected from the following group: halogen, OH, NH2, NHRa , C1-C6 alkyl, C1-C6 haloalkyl, allyl, vinyl, OCD3, OR c , 3-7 membered cycloalkyl, 3-7 membered heterocyclic group, (C1-C4 alkyl) 3-7 membered heterocyclic group, SR c ; Preferably, R2 is selected from the following group: OMe, OCD3.
[0051] In another preferred embodiment, the compound of formula I has a structure as shown in the following formula (II-A), (V), (VI) or (VI-A):
[0052] Preferably, in the formula (II-A), (V), (VI) or (VI-A), each R3' is independently selected from the following group: halogen, OH, SH, NH2, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkylhydroxyl, S(C1-C6 alkyl), allyl, vinyl.
[0053] In another preferred embodiment, the compound of formula I is selected from the following group:
[0054] In another preferred embodiment, the compound of formula I is selected from the following group:
[0055] In another preferred embodiment, the compound of formula I is selected from the following group:
[0056] The second aspect of the present invention provides the use of the compound according to the first aspect of the present invention for preparing a medicament for treating a disease associated with the activity or expression of a KRAS mutant.
[0057] In another preferred embodiment, the disease associated with the activity or expression of the KRAS mutant is a tumor, preferably a tumor selected from the following group: sarcoma, myxoma, rhabdomyomas, fibromas, lipomas, teratomas, bronchial cancer, lung cancer, bronchial adenoma, lymphoma, chondroma, hamartoma, mesothelioma, esophageal cancer, gastric cancer, pancreatic cancer, small intestine cancer, colorectal cancer, genitourinary tract tumors, kidney cancer, bladder cancer, urethral cancer, prostate, testicular cancer, liver cancer, bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, gallbladder cancer, ampullary cancer, bile duct cancer, bone cancer, brain cancer, uterine cancer, vaginal cancer, blood tumors, skin cancer, and breast cancer.
[0058] The third aspect of the present invention provides a pharmaceutical composition comprising: (i) a therapeutically effective amount of a compound of formula I as described in the first aspect of the present invention, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable carrier.
[0059] In another preferred embodiment, the effective amount refers to a therapeutically effective amount or an inhibitory effective amount, preferably 0.01 to 99.99%.
[0060] In another preferred embodiment, the pharmaceutical composition is used to treat diseases related to the activity or expression of KRAS mutants.
[0061] In another preferred embodiment, the KRAS mutant is a KRAS G12D mutant, a KRAS G12V mutant, a KRAS G12S mutant or a KRAS G13D mutant.
[0062] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. DETAILED DESCRIPTION
[0063] After extensive and in-depth research, the inventors prepared a class of compounds having the structure shown in Formula I and discovered that they have the activity of inhibiting KRAS-effector protein-protein interactions and are pan-KRAS inhibitors. Based on these findings, the inventors completed the present invention.
[0064] the term
[0065] As used herein, the term "C1-C6 alkyl" refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, or the like, and "C1-C3 alkyl" and the like have similar definitions.
[0066] The term "C1-C6 alkoxy" refers to a straight or branched alkoxy group having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, or similar groups, and "C1-C3 alkoxy" and other expressions have similar definitions.
[0067] In the present invention, the terms "comprising", "including" or "comprising" indicate that various components can be used together in the mixture or composition of the present invention. Therefore, the terms "consisting mainly of" and "consisting of" are included in the term "comprising".
[0068] In the present invention, the term "pharmaceutically acceptable" refers to a substance that is suitable for use in humans and / or animals without excessive adverse side effects (such as toxicity, irritation, and allergic reactions), that is, has a reasonable benefit / risk ratio.
[0069] As used herein, the term "effective amount" refers to an amount of a therapeutic agent that treats, alleviates, or prevents a target disease or condition, or an amount that exhibits a detectable therapeutic or preventive effect. The precise effective amount for a given subject depends on the subject's size and health, the nature and severity of the condition, and the therapeutic agent and / or combination of therapeutic agents selected for administration. Therefore, it is not useful to specify an exact effective amount in advance. However, for a given condition, the effective amount can be determined by routine experimentation and is within the judgment of the clinician.
[0070] As used herein, unless otherwise specified, the term "substituted" refers to a group where one or more hydrogen atoms are replaced by a substituent selected from the group consisting of halogen, unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C2-C6 acyl, or unsubstituted or halogenated C1-C6 alkyl-hydroxy.
[0071] Unless otherwise specified, all compounds mentioned in the present invention are intended to include all possible optical isomers, such as single chiral compounds or mixtures of various chiral compounds (i.e., racemates). In all compounds of the present invention, each chiral carbon atom may optionally be in the R configuration or the S configuration, or a mixture of the R and S configurations.
[0072] The term "cycloalkyl" includes saturated and partially unsaturated cycloalkyl groups having 3 to 12 carbons, for example 3 to 8 carbons, and as a further example 3 to 6 carbons, wherein the cycloalkyl is optionally substituted with one or more. Examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. The term "cycloalkyl" also includes bridged cycloalkyls, for example, bicyclo[1.1.1]pentyl.
[0073] As used herein, the term "aryl" group is a C6-C14 aromatic moiety comprising one to three aromatic rings. As an example, an aryl group is a C6-C10 aryl group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, fluorenyl, and dihydrobenzofuranyl. "Aryl" also refers to a bicyclic or tricyclic ring system, wherein one or both rings of the aromatic ring system may be saturated or partially saturated, respectively, and wherein if the ring system includes two saturated rings, the saturated rings may be fused or spirocyclic, but the attachment position to the rest of the compound is on the aryl moiety.
[0074] A "heterocyclyl" or "heterocyclic" group is a ring structure having 3 to 12 atoms, e.g., 4 to 8 atoms, wherein one or more atoms are selected from the group consisting of N, O, and S, wherein the ring N atom can be oxidized to NO, and the ring S atom can be oxidized to SO or SO2, and the remaining ring atoms are carbon. A heterocyclyl group can be a monocyclic, bicyclic, spirocyclic, or bridged ring system.
[0075] The term "heteroaryl" refers to a group having 5 to 14 ring atoms, preferably 5, 6, 9 or 10 ring atoms; and in addition to carbon atoms, each ring has one to three heteroatoms selected from N, O and S. "Heteroaryl" also refers to a bicyclic ring system having, in addition to carbon atoms, one to three heteroatoms selected from N, O and S in each ring, wherein one ring system may be saturated or partially saturated.
[0076] The term "halogen" refers to F, Cl, Br and I.
[0077] As used herein, the term "compound of the present invention" refers to a compound of Formula I. The term also includes various crystalline forms, pharmaceutically acceptable salts, hydrates or solvates of the compound of Formula I.
[0078] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention formed with an acid or base that is suitable for pharmaceutical use. Pharmaceutically acceptable salts include inorganic salts and organic salts. A preferred class of salts are salts formed with a compound of the present invention and an acid. Suitable acids for forming salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, phenylmethanesulfonic acid, and benzenesulfonic acid; and acidic amino acids such as aspartic acid and glutamic acid.
[0079] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0080] Preparation Example 1
[0081] Experimental steps:
[0082] Step a:
[0083] At room temperature, raw materials 1-1 (30.0 g), 1-2 (47.0 g), and 126 mL of trifluoroacetic acid were mixed, and the reaction mixture was stirred at 80°C for 16 hours. LCMS indicated completion of the reaction, and the reaction mixture was evaporated in vacuo to yield a crude product. 200 mL of ice water was added, followed by NaOH, and the solution was neutralized to a pH of 8-9. The solution was then extracted with DCM (500 mL x 2). The combined organic phases were washed with saturated brine (300 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated in vacuo to yield the crude product, which was then purified by silica gel column chromatography (MeOH:DCM: = 0.5-2.5%) to yield 1-3 (24.1 g) as a white solid.
[0084] LCMS: (ESI) m / z 304.1 (M+H) + .
[0085] Step b:
[0086] At room temperature, 1-3 (20.0 g) and TEA (18.40 ml) were dissolved in THF (200 ml), and ethyl isocyanate (7.83 ml) was added dropwise. The reaction mixture was stirred at 25°C for 1 hour. After filtration, the mixture was evaporated in vacuo to obtain the crude product. The crude product was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 5%-10%) to obtain Preparation Example 1 (7.0 g) as a white solid.
[0087] MS (ESI) m / z: 375.3 [M+H] + .
[0088] Example 1
[0089] Experimental steps:
[0090] Step a:
[0091] At 0°C, 2-amino-5-bromophenol 1-1 (1.0 g) and sodium bicarbonate (1.34 g) were dissolved in 1,2-dimethoxyethane (25 ml) and water (2 ml), and 2-chloroacetyl chloride (902 mg) was added dropwise with stirring. The reaction mixture was stirred at the same temperature for 30 minutes, then heated and stirred at 80°C for 16 hours. After cooling to room temperature, the reaction mixture was poured into ice water (100 ml). The resulting solid was collected by filtration and lyophilized to obtain 1-2 (1.05 g) as a light brown solid.
[0092] 1 H NMR (400MHz, DMSO-d6) δ10.81 (s, 1H), 7.17-7.12 (m, 2H), 6.83 (d, J = 8.4Hz, 1H), 4.60 (s, 2H).
[0093] Step b
[0094] A solution of borane in tetrahydrofuran (17.5 mL, 1.0 mol) was added dropwise to a solution of starting material 1-2 (2.0 g) in THF (10 mL) at 0°C. The reaction mixture was stirred at 70°C for 3 hours. After cooling, methanol (2 mL) was added dropwise with stirring at 0°C. The reaction mixture was concentrated under reduced pressure and the crude product was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 3 / 1) to yield 1-3 (1.81 g) as a light brown solid.
[0095] MS: m / z 214.1[M+H] + .
[0096] Step c
[0097] The starting material 1-3 (1.8 g), triethylamine (1.7 ng), and di-tert-butyl dicarbonate (2.75 g) were dissolved in dichloromethane (50 ml), and the reaction mixture was stirred at 25°C for 16 hours. After the reaction was complete, the mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 5 / 1) to obtain 1-4 (2.40 g) as a white solid.
[0098] LCMS: m / z 213.9 [M+H-100] + .
[0099] Step d
[0100] Under argon, a mixture of 1-4 (1.78 g, 5.69 mmol), (E)-1-ethoxyvinyl-2-boronic acid pinacol ester (1.69 g, 8.53 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (416 mg, 0.569 mmol), potassium carbonate (2.35 g, 17.06 mmol), 1,4-dioxane (40 mL), and water (10 mL) was heated to 90°C and stirred for 2 hours. The reaction solution was cooled to room temperature, filtered, and then water (10 mL) was added and extracted with ethyl acetate (3 x 20 mL). The combined organic phases were dried and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate 20 / 1-21) to afford 1-5 (1.70 g) as a light yellow solid.
[0101] LCMS: m / z 250.0 [M+H-56] + .
[0102] Steps e and f:
[0103] Intermediate 1-5 (500 mg) was dissolved in dichloromethane (10 ml) and formic acid (1 ml) was added. The reaction solution was stirred at 40 ° C for 16 hours. After the reaction was complete, the mixture was neutralized with saturated sodium bicarbonate aqueous solution (50 ml) and extracted three times with ethyl acetate (50 ml). The organic layers were combined, washed with saturated brine (30 ml), and the organic layer was dried over anhydrous sodium sulfate. After treatment, the reaction solution was concentrated under reduced pressure to obtain the crude product intermediate, which was directly used in the next reaction without separation.
[0104] Sodium borohydride (125 mg, 3.28 mmol) was added to a solution of the crude intermediate (1.0 g) in methanol (20 ml) at 0 degrees. The reaction mixture was stirred at room temperature for 3 hours. After the reaction was completed, water (50 ml) was added and the mixture was extracted three times with ethyl acetate (50 ml). The organic layers were combined, washed with saturated brine (30 ml), and the organic layer was dried over anhydrous sodium sulfate. After treatment, the reaction solution was concentrated under reduced pressure to obtain the crude intermediate. After the reaction mixture was concentrated under reduced pressure, the crude product was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 3 / 1) to obtain 1-6 (304 mg) as a yellow oil.
[0105] 1 H NMR (400MHz, CDCl3): δ7.71 (s, 1H), 6.75-6.73 (m, 2H), 4.23 (d, J = 4.6Hz, 2H), 3.84 (d, J = 4.6Hz, 4H), 2.78 (d, J = 6.6Hz, 2H), 1.54 (s, 9H).
[0106] Step g
[0107] A solution of 1-6 (150 mg, 0.53 mmol), triphenylphosphine (182 mg, 0.7 mmol), and Preparation Example 1 (200 mg, 0.53 mmol) in toluene (10 mL) was purged with argon three times at room temperature, heated to 120°C under argon, and stirred for 10 minutes. Diisopropyl azodicarboxylate (0.14 mL, 0.70 mmol) was then added dropwise. The reaction mixture was stirred at 120°C under argon for 2 hours. After cooling to room temperature, water (50 mL) was added, and the resulting mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate 1 / 1) to yield 1-7 (196 mg) as a white solid.
[0108] LCMS: m / z 636.3 [M+H] + .
[0109] Step h
[0110] Intermediate 1-7 (196 mg, 0.31 mmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (1 mL) was added. The reaction mixture was stirred at 25°C for 16 hours. After the reaction was complete, the mixture was neutralized with aqueous sodium bicarbonate (20 mL) and extracted three times with ethyl acetate (50 mL). The organic layers were combined, washed with saturated brine (30 mL), and dried over anhydrous sodium sulfate. The reaction mixture was concentrated under reduced pressure to obtain the crude product, which was separated using a preparative chromatography column (Waters 2767 / 2545 / 2489 / Qda, Inertsil ODS-3 10 μm 20 x 250 nm, mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile, flow rate: 20 mL / min, column temperature: room temperature) to obtain Example 1 (63.56 mg) as a white solid.
[0111] MS (ESI) m / z: 536.3 [M+H] + ;
[0112] 1 H NMR (400MHz, DMSO-d6) δ7.25(d,J=2.0Hz,1H),7.08(dd,J=8.4Hz,1H),6.76(s,1H),6.67(t,J=5.4 Hz,1H),6.54–6.49(m,5H),6.44(d,J=7.6Hz,1H),6.54(s,1H),4.07(t,J=4.2Hz,2H),3.96–3.90( m,1H),3.83–3.76(m,1H),3.75(s,3H),3.73–3.69(m,1H),3.22(t,J=4.0Hz,2H),3.10–3.08(m,2H ),2.97–2.80(m,2H),2.74(t,J=7.4Hz,2H),2.57–2.54(m,1H),2.40(s,3H),1.01(t,J=7.2Hz,3H).
[0113] Example 2
[0114] Step a:
[0115] Under argon, 2-1 (10.0 g) and 1,2-dithiohydroxyethane (4.5 g) were added to anhydrous toluene (450 ml), followed by p-toluenesulfonic acid (200 mg). The mixture was stirred at 120°C for 24 hours. After the reaction was complete, the reaction solution was concentrated to dryness and then concentrated under reduced pressure to obtain a crude product. The crude product was purified on a silica gel column (petroleum ether / ethyl acetate = 20:1) to obtain 2-2 (12.0 g) as a pale yellow solid.
[0116] 1 H NMR (400MHz, CDCl3) δ7.42-7.40(m,1H),7.37-7.32(m,2H),3.57-3.49(m,2H),3.46-3.39(m,2H),2.85(t,J=6.8Hz,2H),2.67(t,J=6.8Hz,2H).
[0117] Step b:
[0118] At -70°C under argon, pyridine hydrofluoride (130 g, 0.94 mol, 70% w / w) was added to a solution of 1,3-dibromo-5,5-dimethylimidazoline-2,4-dione (24 g) in dichloromethane (200 mL). A solution of 2-2 (6.0 g) in dichloromethane (40 mL) was then added dropwise to the solution at -60°C. The mixture was stirred at the same temperature for 4 hours, then allowed to warm to room temperature and stirred for a further 12 hours. The reaction mixture was washed three times with 2.0 M aqueous NaOH (80 mL x 3) and then with aqueous sodium bisulfite (80 mL x 2). The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was then purified on a silica gel column (petroleum ether / ethyl acetate = 20 / 1) to afford 2-3 (5.2 g) as an oil.
[0119] 1 H NMR (CDCl3, 400MHz): δ7.72 (s, 1H), 7.59 (d, J = 8.4Hz, 1H), 7.16 (d, J = 8.0Hz, 1H), 4.61–4.51 (m, 1H), 3.52–3.48 (m, 1H), 3.23–3.15 (m, 1H).
[0120] Step c:
[0121] At 0°C, intermediate 2-3 (5.4 g) was dissolved in dichloromethane (200 ml), and 1,8-diazabicycloundec-7-ene (DBU) (3.95 g) was added dropwise. The reaction was stirred at room temperature for 16 hours. After the reaction was complete, the reaction solution was concentrated to dryness, and the crude product was purified on a silica gel column (petroleum ether / ethyl acetate = 20 / 1) to obtain 2-4 (2.90 g) as an oil.
[0122] Step d:
[0123] To a stirred solution of crude product 2-4 (2.9 g, 12.6 mmol) and potassium phosphate (0.530 g, 2.51 mmol) in acetonitrile (20 mL) at 0°C were added 2-nitrosulfonyl chloride (2.78 g, 12.6 mmol) and hydrazine hydrate (1.48 g, 25.1 mmol). The reaction mixture was then stirred at 60°C for 16 hours. After cooling, water (20 mL) was added to the reaction mixture. The resulting mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether) to afford 2-5 (2.5 g) as a colorless oil.
[0124] 1 H NMR (CDCl3, 400MHz): δ7.66 (s, 1H), 7.58 (d, J = 10.0Hz, 1H), 7.50 (d, J = 8.4Hz, 1H), 3.07-3.20 (m, 2H), 2.64-2.54 (m, 2H).
[0125] Step e:
[0126] Under argon, a mixture of 2-5 (1 g, 4.29 mmol), (E)-1-ethoxyvinyl-2-boronic acid pinacol ester (1.27 g, 6.44 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (314 mg, 0.43 mmol), potassium carbonate (1.78 g, 12.88 mmol), 1,4-dioxane (15 mL), and water (5 mL) was heated to 90°C and stirred for 5 hours. The reaction mixture was cooled to room temperature, filtered, and then water (50 mL) was added and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated by silica gel column chromatography (eluent: petroleum ether) to afford 2-6 (614 mg) as a yellow solid.
[0127] 1 H NMR (CDCl3, 400MHz): δ7.42 (d, J = 8.0Hz, 1H), 7.18 (d, J = 8.0Hz, 1H), 7.12 (s, 1H), 7.03 (d, J = 12.8Hz, 1H) ,5.85(d,J=12.8Hz,1H),3.94-3.89(m,2H),3.01-2.97(m,2H),2.59-2.55(m,2H),1.36(t,J=3.4Hz,3H).
[0128] Step f:
[0129] Concentrated hydrochloric acid (1.5 mL) was added to a solution of 2-6 (324 mg, 1.45 mmol) in tetrahydrofuran (10 mL) at 0°C. The mixture was stirred at 0°C for 3 hours. Water (50 mL) was added to the resulting mixture, which was then extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to yield the crude intermediate (520 mg) as a yellow oil. This was used directly in the next reaction.
[0130] Step g:
[0131] To a stirred solution of the crude intermediate (520 mg, 1.321 mmol) in dry tetrahydrofuran (20 mL) at 0°C was added sodium borohydride (60 mg, 1.59 mmol). The reaction mixture was then stirred at the same temperature for 3 hours. Water (50 mL) was added to the reaction mixture. The mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate 3 / 1, v / v) to afford 2-7 (112 mg) as a brown oil.
[0132] 1 H NMR (CDCl3, 400MHz): δ7.49 (d, J = 7.6Hz, 1H), 7.24-7.20 (m, 2H), 7.17 (s, 1H) ,3.90-3.86(m,2H),3.04-3.00(m,2H),2.92-2.86(m,2H),2.64-2.53(m,2H).
[0133] Step h:
[0134] A solution of Preparation Example 1 (100 mg, 0.26 mmol), triphenylphosphine (100 mg, 0.38 mmol), and 2-7 (50 mg, 0.26 mmol) in toluene (5 mL) was purged with argon three times at room temperature, heated to 120°C under argon, and stirred for 10 minutes. Diisopropyl azodicarboxylate (0.07 mL, 0.38 mmol) was then added dropwise. The reaction mixture was stirred at 120°C under argon for 2 hours. After cooling to room temperature, water (50 mL) was added, and the resulting mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate 1 / 1) to yield Example 2 (20.78 mg) as a white solid.
[0135] 1H NMR(400MHz, DMSO-d6)δ7.44(d,J=8.0Hz,1H),7.29–7.26(m,2H),7.09(d,J=8 .0Hz,1H),6.77(s,1H),6.68(t,J=5.4Hz,3H),6.53(t,J=9.2Hz,3H),4.08–4. 06(m,1H),3.96–3.94(m,1H),3.76(s,3H),3.73–3.71(m,1H),3.10–3.08(m,2 H),3.03–2.93(m,6H),2.85–2.52(m,2H),2.40(s,3H),1.01(t,J=6.0Hz,3H).
[0136] MS (ESI) m / z: 555.2 [M+H] + ;
[0137] Example 3
[0138] The preparation of Example 3 was similar to that of Example 7. 2-(Benzo[d]oxazol-5-yl)ethan-1-ol (30 mg) and Preparation 1 (69 mg) were used to give Example 3 (33.12 mg) as a white solid.
[0139] MS (ESI): m / z 520.2 [M+H] + .
[0140] 1 H NMR(400MHz, DMSO-d6)δ8.69(s,1H),7.72(s,1H),7.65(d,J=8.0Hz,1H),7.35–7.33(m, 1H),7.23(d,J=2.0Hz,1H),7.10–7.07(m,1H),6.77(s,1H),6.69–6.66(m,1H),6.54–6. 48(m,3H),4.11–4.06(m,1H),4.01–3.97(m,1H),3.76(s,3H),3.74–3.69(m,1H),3.11– 3.04(m,4H),2.95–2.78(m,2H),2.57–2.56(m,1H),2.39(s,3H),1.00(t,J=7.2Hz,3H).
[0141] Example 4
[0142] Step a:
[0143] Methyl 2-(3-amino-4-hydroxyphenyl)acetate 4-1 (2.00 g, 11.0 mmol) was dissolved in ethyl acetate (4 ml) and water (4 ml). Sodium bicarbonate (1.00 g, 12.1 mmol) and chloroacetyl chloride (1.42 ml, 11.0 mmol) were added at 0°C and the mixture was stirred at room temperature for 3 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate (20 ml) and brine (20 ml). The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was dissolved in N,N-dimethylformamide (50 ml) and potassium carbonate (3.36 g, 22.0 ml) was added. The reaction was heated to 80°C and stirred for 3 hours. After the reaction was completed by TLC monitoring, the reaction was cooled to room temperature, diluted with water (100 mL), extracted with ethyl acetate (100 mL * 3), the organic phases were combined, washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give methyl 2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acetate 4-2 (1.7 g, yellow oily product).
[0144] MS (ESI): m / z 222.1 [M+H] +
[0145] Step b:
[0146] To a solution of 2-(3-oxo-3,4-dihydro-2H-benzo[b-[1,4]oxazin-6-yl)acetate 4-2 (1.70 g, 7.70 mmol) in tetrahydrofuran (20 mL) was added lithium aluminum hydride (0.73 g, 19.3 mmol) portionwise at 0°C, and the reaction was stirred at room temperature overnight. After completion of the reaction, as monitored by LC-MS, the resulting mixture was quenched with water (0.8 mL), followed by addition of aqueous sodium hydroxide (0.8 mL, 3.0 M) and water (2.4 mL) at 0°C. The resulting mixture was filtered through Celite, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 1 to 20 / 1) to afford 2-(3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)ethan-1-ol 4-3 (500 mg, yellow oil).
[0147] MS (ESI): m / z 180.1 [M+H] +
[0148] Step c:
[0149] To a solution of 2-(3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)ethan-1-ol 4-3 (500 mg, 2.79 mmol) in dichloromethane (20 mL) were added triethylamine (1.10 mL, 8.40 mmol), di-tert-butyl dicarbonate (730 mg, 3.38 mmol), and 4-dimethylaminopyridine (100 mg, 0.820 mmol). The mixture was stirred at room temperature overnight. After completion of the reaction, as monitored by LC-MS, the reaction solution was concentrated in vacuo, and the resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1 to 1 / 1) to afford tert-butyl 6-(2-hydroxyethyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate 4-4 (80 mg, white solid) in a yield of 10.2%.
[0150] MS (ESI): m / z 180.1 [M-Boc+H] +
[0151] Step d:
[0152] To a solution of tert-butyl 6-(2-hydroxyethyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate 4-4 (80 mg, 0.286 mmol) in toluene (5 mL) were added Preparation Example 1 (107 mL, 0.286 mmol) and triphenylphosphine (90 mg, 0.343 mmol) in sequence. Under argon, the reaction mixture was heated to 105°C and stirred for 30 minutes. Diisopropyl azodicarboxylate (70 mg, 0.343 mmol) was added and the reaction was stirred for 3 hours. After the reaction was completed as monitored by LC-MS, the reaction mixture was cooled to room temperature, diluted with brine (20 mL), extracted with ethyl acetate (20 mL×3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give tert-butyl 6-(2-((1-(4-chloro-2-methylphenyl)-2-(ethylcarbamoyl)-6-methoxy-1,2-tetrahydroisoquinolin-7-yl)oxy)ethyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate 4-5 (150 mg, yellow oil).
[0153] MS (ESI): m / z 658.3 [M+Na] +
[0154] Step e:
[0155] A mixture of 4-5 (150 mg, 0.236 mmol) and hydrochloric acid / dioxane (5 mL, 4.0 M) was stirred at room temperature for 2 hours. After completion of the reaction, as monitored by LC-MS, the reaction mixture was concentrated in vacuo, and the resulting residue was purified by preparative HPLC (NH4HCO3) to afford Example 4 (13.83 mg, white solid).
[0156] MS (ESI): m / z 536.3 [M+H] +
[0157] 1 H NMR (400MHz, CDCl3) δ7.17 (d, J=1.8Hz, 1H), 6.97 (dd, J=8.3, 1.9Hz, 1H), 6.91–6.76 (m, 3H),6.63(s,1H),6.56(d,J=8.3Hz,1H),6.27(d,J=51.4Hz,3H),4.35(d,J=4.7Hz,2H), 4.20–4.04(m,2H),3.85(s,3H),3.59–3.43(m,3H),3.33–3.20(m,3H),3.05–2.85(m,3H ),2.62(dd,J=16.7,3.3Hz,1H),2.40(s,3H),1.30–1.24(m,1H),1.11(t,J=7.2Hz,3H).
[0158] Implementation 5
[0159] Step a:
[0160] 6-Bromobenzothiophene 5-1 (1.10 g, 5.2 mmol) was added to dioxane (30 ml) and water (6 ml), followed by (E)-1-ethoxyvinyl-2-boronic acid pinacol ester (1.5 g, 7.7 mmol), 1,1'-bis(diphenylphosphinoferrocenedichloridopalladium) (190 mg, 0.26 mmol), and potassium carbonate (2.10 g, 15.2 mmol). The mixture was then purged with argon three times, the system heated to 80°C, and reacted at 80°C for 3 hours under argon protection. After the reaction was complete, the mixture was cooled to room temperature, diluted with water (30 ml), and extracted with ethyl acetate (30 ml x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue, which was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 1-20 / 1) to obtain the target compound (E)-6-(2-ethoxyvinyl)benzo[b]thiophene 5-2 (900 mg) as a light yellow solid.
[0161] Step b:
[0162] Intermediate 5-2 (900 mg, 4.41 mmol) was dissolved in 5 ml of tetrahydrofuran solution, and 1.5 ml of concentrated hydrochloric acid was added at 0°C. The resulting mixture was stirred at 0°C for 4 hours. After the reaction was complete, it was diluted with water (30 ml) and extracted with ethyl acetate (30 ml × 3). The organic layers were combined and washed with brine (30 ml), dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product 5-3 (700 mg) of 2-(benzo[b]thiophene-6-yl)acetaldehyde as a light yellow oil, which was used directly in the next step.
[0163] Step c:
[0164] Compound 5-3 (700 mg) was dissolved in methanol (5 mL), and sodium borohydride (151 mg, 3.98 mmol) was added at 0°C. The mixture was then stirred at room temperature for 1 hour. After completion of the reaction, the pH of the reaction solution was adjusted to 5 with dilute hydrochloric acid, followed by extraction with ethyl acetate (50 mL x 2). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1 to 2 / 1) to yield the target compound, 2-(benzo[b]thiophen-6-yl)ethan-1-ol 5-4 (290 mg), as a light yellow oil.
[0165] 1 H NMR (400MHz, CDCl3) δ7.75(t,J=6.6Hz,2H),7.39(d,J=5.6Hz,1H),7.30(t,J =2.8Hz,1H),7.22–7.25(m,1H),3.90(t,J=6.6Hz,2H),2.96(t,J=6.4Hz,2H).
[0166] Step d:
[0167] Compound 1-(4-chloro-2-methylphenyl)-N-ethyl-7-hydroxy-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxamide Preparation Example 1 (80 mg, 0.21 mmol) was added to 5 ml of toluene, followed by the addition of triphenylphosphine (73 mg, 0.28 mmol) and 5-4 (38.0 mg, 0.21 mmol). The mixture was then purged with argon three times. The resulting mixture was heated at 120°C for 10 minutes, and then diisopropyl azodicarboxylate (0.05 ml, 0.28 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred at 120°C for another 3 hours. After the reaction was complete, the resulting mixture was cooled to room temperature, diluted with 10 ml of water, and extracted with ethyl acetate (30 ml x 2). The combined organic layers were washed with 20 ml of saturated brine and dried over anhydrous sodium sulfate. The organic phase was filtered and concentrated to obtain the residue, which was purified by preparative plate (dichloromethane / methanol = 42 / 1) to give Example 5 (25.75 mg) as a white solid.
[0168] MS (ESI): m / z 535.3 [M+H] + .
[0169] H NMR (400MHz, DMSO-d6) δ7.86 (s, 1H), 7.77 (d, J = 8.0Hz, 1H), 7.67 (d, J = 5.2Hz, 1H), 7.39 (d, J = 5.6Hz, 1H),7.29–7.27(m,1H),7.24(d,J=2.4Hz,1H),7.09–7.06(m,1H),6.76(s,1H),6.66(t,J=5.2Hz,1H) ,6.53(t,J=4.2Hz,2H),6.48(s,1H),4.11–4.07(m,1H),4.02–3.97(m,1H),3.75(s,3H),3.72–3.68( m,1H),3.10–3.03(m,4H),2.92–2.79(m,2H),2.67–2.56(m,1H),2.33(s,3H),1.00(t,J=7.2Hz,3H).
[0170] Example 6
[0171] Step a:
[0172] To a mixture of 1,2-dibromoethane (7.55 ml, 87.3 mmol), potassium carbonate (24.1 g, 175 mmol), and 100 ml of acetonitrile was added 2,5-dibromophenol 6-1 (11.0 g, 43.6 mmol) at room temperature. The reaction system was stirred at 80°C for 18 hours. After completion of the reaction, the mixture was cooled to room temperature, 200 ml of water was added, and the mixture was extracted with ethyl acetate (100 ml x 2). The combined organic layers were washed with saturated brine (100 ml), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified on a silica gel column (eluent: petroleum ether / ethyl acetate = 100 / 1 to 50 / 1) to afford 1,4-dibromo-2(2-bromoethoxy)benzene 6-2 (4.00 g) as a colorless oil.
[0173] 1 H NMR (400MHz, DMSO-d6) δ7.54(d,J=8.4Hz,1H),7.35(d,J=2.1Hz,1H),7.12(dd,J=8.4,2.1Hz,1H),4.48–4.43(m,2H),3.84–3.79(m,2H).
[0174] Step b:
[0175] n-Butyllithium (7.31 mL, 11.7 mmol, 1.6 M / hexane) was slowly added to a solution of tetrahydrofuran (5 mL) and 1,4-dibromo-2(2-bromoethoxy)benzene 6-2 (4.20 g, 11.7 mmol) at -70°C under nitrogen. The reaction mixture was stirred at -70°C for 1 hour, then quenched by the addition of 5 mL of acetic acid. The reaction mixture was diluted with 50 mL of water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with 50 mL of saturated brine and dried over anhydrous sodium sulfate. The organic phase was filtered and the residue was concentrated under reduced pressure. The residue was purified on a silica gel column (eluent: petroleum ether / ethyl acetate = 1 / 0 to 100 / 1) to yield 6-bromo-2,3-dihydrobenzofuran 6-3 (1.20 g) as a white solid.
[0176] 1 H NMR (400MHz, CDCl3) δ7.03 (d, J = 7.8Hz, 1H), 6.98–6.92 (m, 2H), 4.58 (t, J = 8.7Hz, 2H), 3.15 (t, J = 8.5Hz, 2H).
[0177] Step c:
[0178] 6-Bromo-2,3-dihydrobenzofuran 6-3-ol (1.15 g, 5.84 mmol), (E)-1-ethoxyvinyl-2-boronic acid pinacol ester (1.73 g, 8.76 mmol), potassium carbonate (2.42 g, 17.5 mmol), and 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (427 mg, 0.58 mmol) were added to a mixture of 20 mL of dioxane and 5 mL of water. The reaction system was purged with argon three times, then heated to 80°C and stirred at this temperature for 2 hours. The reaction solution was diluted with 50 mL of water (50 mL each) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with 50 ml of saturated brine and dried over anhydrous sodium sulfate. The organic phase was filtered and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1-1 / 1) to give 6-4 (1.00 g) as a light yellow solid.
[0179] MS (ESI): m / z 191.2 [M+H] + .
[0180] Step d:
[0181] To a solution of (E)-6-(2-ethoxyvinyl)-2,3-dihydrobenzofuran 6-4 (200 mg, 1.06 mmol) and 5 mL of tetrahydrofuran was added 1.1 mL of concentrated hydrochloric acid at 0°C. The system was stirred at 0°C for 3 hours, then 20 mL of water was added and extracted with ethyl acetate (20 mL x 2). The organic layers were combined, washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield crude 2-(2,3-dihydrobenzofuran-6-yl)acetaldehyde 6-5 (554 mg) as a yellow oil, which was used directly in the next reaction.
[0182] Step e:
[0183] To a solution of intermediate 6-5 (554 mg, 3.42 mmol) and methanol (10 mL) was added sodium borohydride (51 mg, 1.06 mmol) at 0°C. The mixture was stirred at room temperature for 1 hour. The pH was adjusted to 5 with 1 N (1 N) dilute hydrochloric acid, followed by extraction with ethyl acetate (50 mL x 2). The combined organic layers were washed with 50 mL of saturated brine and dried over anhydrous sodium sulfate. The organic phase was filtered and concentrated under reduced pressure to obtain a residue, which was purified on a silica gel column (eluent: petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to yield 6-6 (230 mg) as a light brown oil.
[0184] 1H NMR(400MHz, CDCl3)δ7.12(d,J=7.6Hz,1H),6.70–6.72(m,1H),6.67(s,1H),4.56 (t,J=8.8Hz,2H),3.83–3.84(m,2H),3.18(t,J=8.6Hz,2H),2.82(t,J=6.4Hz,2H).
[0185] Step f:
[0186] The preparation of Example 6 was carried out in a manner similar to that of Example 5. 6-6 (43.9 mg, 0.27 mmol) and Preparation 1 (100 mg) were used to obtain Example 6 (24.37 mg) as a white solid.
[0187] MS (ESI): m / z 521.3 [M+H] + .
[0188] 1 H NMR(400MHz,DMSO-d6)δ7.24(d,J=2.0Hz,1H),7.06–7.09(m,2H),6.76(s,1 H),6.65–6.69(m,3H),6.48–6.53(m,3H),4.47(t,J=8.6Hz,2H),3.98–4.00( m,1H),3.86–3.88(m,1H),3.76(s,3H),3.68–3.75(m,1H),3.05–3.11(m,4H ),2.83–2.92(m,4H),2.56–2.80(m,1H),2.39(s,3H),1.00(t,J=7.0Hz,3H).
[0189] Example 7
[0190] Step a:
[0191] Under argon, a mixture of 7-1 (1.4 g, 7.1 mmol), (E)-1-ethoxyvinyl-2-boronic acid pinacol ester (2.10 g, 10.6 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (260 mg, 0.36 mmol), potassium carbonate (2.00 g, 14.5 mmol), 1,4-dioxane (30 mL), and water (6 mL) was heated to 80°C and stirred for 3 hours. The reaction mixture was cooled to room temperature, filtered, and then water (20 mL) was added and extracted with ethyl acetate (3 x 30 mL). The combined organic phases were dried and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate 20 / 1 to 10 / 1) to afford 7-2 (1.10 g) as a light yellow solid.
[0192] 1 H NMR (400MHz, CDCl3) δ8.01 (s, 1H), 7.64 (d, J = 8.4Hz, 1H), 7.40 (s, 1H), 7.27-7.23 (m, 1H), 7 .03(d,J=12.8Hz,1H),5.95(d,J=13.2Hz,1H),3.93(q,J=7.1Hz,2H),1.36(t,J=7.0Hz,3H).
[0193] Step b:
[0194] A solution of 7-2 (250 mg, 1.321 mmol) in formic acid (3.5 mL) was stirred at room temperature for 3 hours. The resulting mixture was added with saturated aqueous sodium bicarbonate (30 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to afford crude 7-3 (213 mg) as a yellow oil, which was used directly in the next reaction.
[0195] Step c:
[0196] To a stirred solution of crude product 7-3 (213 mg, 1.321 mmol) in methanol (10 mL) was added sodium borohydride (50 mg, 1.321 mmol) at 0°C. The reaction mixture was then stirred at the same temperature for 1 hour. Dilute hydrochloric acid (1.0 M) was added to the reaction mixture to quench the reaction until pH = 5. The resulting mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate 10 / 1 to 1 / 1) to obtain 7-4 (60 mg) as a brown oil.
[0197] 1 H NMR (400MHz, CDCl3) δ8.06 (s, 1H), 7.72 (d, J = 8.0Hz, 1H), 7.48 (d, J = 0.4Hz, 1H), 7.25 (dd, J = 8.4, 1.2Hz, 1H), 3.93 (t, J = 6.4Hz, 2H), 3.02 (t, J = 6.4Hz, 2H).
[0198] Step d:
[0199] A solution of Preparation Example 1 (168 mg, 0.448 mmol), triphenylphosphine (126 mg, 0.4785 mmol), and 7-4 (60 mg, 0.368 mmol) in toluene (5 mL) was purged with argon three times at room temperature, heated to 120°C under argon, and stirred for 10 minutes. Diisopropyl azodicarboxylate (0.08 mL, 0.4785 mmol) was then added dropwise. The reaction mixture was stirred at 120°C under argon for 3 hours. After cooling to room temperature, water (10 mL) was added, and the resulting mixture was extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate 10 / 1 to 1 / 2) and further by preparative thin layer chromatography (developing solvent: dichloromethane / methanol = 40 / 1) to give Example 7 (35.23 mg) as a white solid.
[0200] 1 H NMR (400MHz, DMSO-d6) δ8.66 (s, 1H), 7.69-7.66 (m, 2H), 7.30 (dd, J = 8.2, 1.4Hz, 1H), 7.2 4(d,J=2.4Hz,1H),7.07(dd,J=8.4,2.4Hz,1H),6.76(s,1H),6.66(t,J=5.4Hz,1H),6.53 -6.48(m,3H),4.11-4.08(m,1H),4.07-3.97(m,1H),3.75(s,3H),3.72-3.68(m,1H),3.1 2-3.04(m,4H),2.95-2.75(m,2H),2.56-2.55(m,1H),2.39(s,3H),1.00(t,J=7.2Hz,3H).
[0201] LC-MS (ESI): m / z 520.2 [M+H] + .
[0202] Example 8
[0203] Step a:
[0204] A mixture of 8-1 (2.3 g, 10.74 mmol), potassium ethylene trifluoroborate (2.16 g, 16.12 mmol), bis(triphenylphosphine)palladium dichloride (754 mg, 1.07 mmol), potassium carbonate (4.45 g, 32.2 mmol), 1,4-dioxane (100 mL), and water (20 mL) was heated to 90°C and stirred under argon for 5 hours. The reaction mixture was cooled to room temperature, water (100 mL) was added, and the resulting mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1) to yield 8-2 (1.30 g) as a colorless oil.
[0205] LC-MS (ESI): m / z 162.0 [M+H] + .
[0206] Step b:
[0207] To a stirred solution of 8-2 (1.3 g, 8.06 mmol) in tetrahydrofuran (100 mL) was added dropwise a solution of 9-BBN in tetrahydrofuran (0.5 M, 24.2 mL, 12.1 mmol) at room temperature under argon. The reaction was then heated to 80°C and stirred under argon for 4 hours. The reaction was cooled to room temperature, and hydrogen peroxide (30% aqueous solution, 4.57 g, 40.32 mmol) was added dropwise with stirring. The resulting mixture was heated to 80°C and stirred for 1 hour. The reaction was cooled to room temperature and extracted with ethyl acetate (2 x 100 mL). The combined organic phases were washed with water (2 x 100 mL), washed with aqueous sodium sulfite (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to yield 8-3 (620 mg) as a light yellow oil.
[0208] LC-MS (ESI): m / z 180.1 [M+H] + .
[0209] Step c:
[0210] A solution of 8-3 (150 mg, 0.837 mmol), Preparation 1 (313 mg, 0.835 mmol), and triphenylphosphine (263 mg, 1.00 mmol) in dry tetrahydrofuran (10 mL) was purged with argon three times at room temperature, cooled to 0°C under argon, and a solution of diisopropyl azodicarboxylate (0.199 mL, 1.00 mmol) in tetrahydrofuran (3 mL) was added dropwise with stirring. The reaction mixture was then returned to room temperature and stirred under argon for 2 hours. The reaction solution was concentrated, and the resulting residue was separated by preparative HPLC (Waters 2767 / 2545 / 2489 / Qda, Inertsil ODS-3 10 μm 20*250 nm, mobile phase A: 0.1% formic acid aqueous solution, mobile phase B: acetonitrile, flow rate: 20 ml / min, column temperature: room temperature) to obtain Example 8 (27.4 mg) as a white solid.
[0211] LC-MS (ESI): m / z 536.3 [M+H] + .
[0212] 1 H NMR (400MHz, DMSO-d6) δ9.35 (s, 1H), 8.15-7.97 (m, 2H), 7.45-7.37 (m, 1H), 7.24 (d, J= 2.1Hz,1H),7.07(dd,J=8.3,2.2Hz,1H),6.76(s,1H),6.67(t,J=5.4Hz,1H),6.58-6.4 2(m,3H),4.14-4.08(m,1H),4.05-3.98(m,1H),3.74(s,3H),3.73-3.65(m,1H),3.16- 3.05(m,4H),2.95-2.70(m,2H),2.58-2.53(m,1H),2.38(s,3H),1.00(t,J=7.1Hz,3H).
[0213] Example 9
[0214] Example 9 was prepared in a manner similar to Example 8. 2-(Benzo[d-]thiazol-6-yl)ethanol-1 (200 mg, 1.116 mmol) and Preparation 1 (349 mg, 0.931 mmol) were reacted to give Example 9 (151.26 mg) as a white solid.
[0215] LC-MS (ESI): m / z 536.1 [M+H] + .
[0216] 1H NMR(400MHz,DMSO-d6)δ9.32(s,1H),8.03(d,J=1.2Hz,1H),7.98(d,J=8.4Hz,1H) ,7.45(dd,J=8.4,1.6Hz,1H),7.24(d,J=2.0Hz,1H),7.08(dd,J=8.2,2.2Hz,1H), 6.77(s,1H),6.67(t,J=5.4Hz,1H),6.55-6.50(m,2H),6.49(s,1H),4.15-4.08(m ,1H),4.04-3.96(m,1H),3.75(s,3H),3.74-3.67(m,1H),3.14-3.03(m,4H),2.97- 2.87(m,1H),2.86-2.75(m,1H),2.58-2.52(m,1H),2.39(s,3H),1.00(t,J=7.1Hz,3H).
[0217] Example 10
[0218] Step a:
[0219] To a mixture of 10-1 (8.00 g, 40.6 mmol), 1,4-dioxane (150 mL), and water (50 mL) were added potassium ethylene trifluoroborate (8.16 g, 60.9 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (1.48 g, 2.03 mmol), and cesium carbonate (39.7 g, 122 mmol) at room temperature under argon. The reaction mixture was then heated to 100°C and stirred under argon for 16 hours. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to yield 10-2 (4.30 g) as a yellow solid.
[0220] LC-MS (ESI): m / z 145.1 [M+H] + .
[0221] Step b:
[0222] To a stirred solution of 10-2 (1.00 g, 6.94 mmol) in tetrahydrofuran (10 mL) were added di-tert-butyl dicarbonate (4.45 mL, 20.8 mmol) and 4-dimethylaminopyridine (0.42 g, 3.47 mmol) at room temperature. The reaction mixture was then stirred at room temperature for 3 hours. The reaction mixture was diluted with water (100 mL) and extracted with dichloromethane (2 x 100 mL). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 1 to 80 / 1) to afford 10-3 (1.10 g) as a yellow solid.
[0223] LC-MS(ESI):m / z 189.1[Mt-Bu+2H] + .
[0224] Step c:
[0225] To a stirred mixture of borane in tetrahydrofuran (1.0 M, 4.91 mL, 4.91 mmol) and dry tetrahydrofuran (20 mL) at 0°C under argon was added a solution of 10-3 (800 mg, 3.28 mmol) in tetrahydrofuran (30 mL) dropwise. The reaction mixture was then allowed to return to room temperature and stirred overnight under argon. Aqueous sodium hydroxide (3.0 M, 1.64 mL, 4.92 mmol) and hydrogen peroxide (30% aqueous solution, 0.493 mL, 4.91 mmol) were added dropwise. The resulting mixture was heated to 80°C and stirred for 5 hours. After cooling to room temperature, the reaction mixture was diluted with water (40 mL) and extracted with dichloromethane (2 x 100 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and the resulting residue was separated by silica gel column chromatography (eluent: dichloromethane / methanol = 40 / 1) to obtain 10-4 (500 mg) as a yellow solid.
[0226] LC-MS (ESI): m / z 263.0 [M+H] + .
[0227] Step d:
[0228] A solution of 10-4 (200 mg, 0.762 mmol), 30-3 (239 mg, 0.635 mmol), and triphenylphosphine (200 mg, 0.762 mmol) in dry tetrahydrofuran (10 mL) was purged with argon three times at room temperature. The mixture was cooled to 0°C under argon and a solution of diisopropyl azodicarboxylate (0.151 mL, 0.762 mmol) in tetrahydrofuran (10 mL) was added dropwise with stirring. The reaction mixture was then returned to room temperature and stirred under argon for 3 hours. The reaction mixture was concentrated, and the resulting residue was diluted with water (50 mL) and extracted with dichloromethane (2 x 100 mL). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and the resulting residue was separated by silica gel column chromatography (eluent: dichloromethane / methanol = 50 / 1 to 10 / 1) to give 10-5 (210 mL) as a yellow solid.
[0229] LC-MS (ESI): m / z 619.2 [M+H] + .
[0230] Step e:
[0231] A mixture of 10-5 (150 mg, 0.242 mmol) and a hydrogen chloride / 1,4-dioxane solution (4.0 M, 10 mL, 40 mmol) was stirred at room temperature for 4 hours. The reaction mixture was concentrated, and the resulting residue was separated by preparative HPLC (Waters 2767 / 2545 / 2489 / Qda, Inertsil ODS-3 10 μm 20 x 250 nm, mobile phase A: 0.1% formic acid solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to afford Example 10 (33.16 mg) as a white solid.
[0232] LC-MS (ESI): m / z 519.3 [M+H] + .
[0233] 1H NMR(400MHz,DMSO-d6)δ12.93(s,1H),7.96(s,1H),7.58(s,1H),7.43(d,J=8.5Hz,1H), 7.29-7.17(m,2H),7.08(dd,J=8.3,2.1Hz,1H),6.76(s,1H),6.66(t,J=5.3Hz,1H),6.55 -6.47(m,3H),4.10-4.04(m,1H),3.96-3.92(m,1H),3.75(s,3H)3.74-3.66(m,1H),3.13 -2.98(m,4H),2.96-2.72(m,2H),2.56-2.51(m,1H),2.39(s,3H),1.00(t,J=7.1Hz,3H).
[0234] Example 11
[0235] Example 11 was prepared in a similar manner to Example 10. 2-(Benzo[d-]pyrazol-6-yl)ethanol-1-ol (100 mg, 0.381 mmol) and Preparation 1 (142 mg, 0.379 mmol) were reacted to give a white solid intermediate (30 mg).
[0236] A mixture of the intermediate (30 mg, 0.048 mmol) and a hydrogen chloride / 1,4-dioxane solution (4.0 M, 3 mL, 12 mmol) was stirred at room temperature for 2 hours. The reaction mixture was concentrated, and the resulting residue was separated by preparative HPLC (mobile phase containing ammonium bicarbonate) to afford Example 11 (6.67 mg) as a white solid.
[0237] LC-MS (ESI): m / z 519.3 [M+H] + .
[0238] 1H NMR (400MHz, DMSO-d6) δ12.91(s,1H),7.98(s,1H),7.63(d,J=8.0Hz,1H),7.40(s,1H) ,7.24(d,J=2.0Hz,1H),7.09-7.00(m,2H),6.76(s,1H),6.67(t,J=5.2Hz,1H),6.54-6. 48(m,3H),4.11-4.04(m,1H),4.00-3.92(m,1H),3.74(s,3H),3.74-3.69(m,1H),3.10- 3.04(m,4H),2.96-2.65(m,2H),2.60-2.52(m,1H),2.39(s,3H),1.00(t,J=7.1Hz,3H).
[0239] Example 12
[0240] The preparation of Example 12 was obtained by a method similar to that of Example 2. 2-(3,3-difluoro-2,3-dihydro-1H-inden-5-yl-5-yl)ethan-1-ethan-1-ol (53.0 mg) and Preparation 1 (100 mg) were used to obtain Example 12 (35.25 mg) as a white solid.
[0241] 1 H NMR (400MHz, DMSO-d6) δ7.47(s,1H),7.39(d,J=8.0Hz,1H),7.28(d,J=8.0Hz,1H),7.24 (s,1H),7.07(d,J=8.0Hz,1H),6.76(s,1H),6.66(s,1H),6.51(t,J=10.0Hz,3H),4.08–4 .02(m,1H),3.96–3.90(m,1H),3.74(s,3H),3.69–3.67(m,1H),3.08–3.05(m,2H),3.03 –2.75(m,6H),2.57–2.52(m,2H),2.39(s,3H),2.28–2.25(m,1H),1.00(t,J=6.0Hz,3H).
[0242] MS (ESI) m / z: 555.2 [M+H] + ;
[0243] Implementation 13
[0244] Example 13 was prepared in a manner similar to Example 6. The starting material 5-(2-hydroxyethyl)-2,3-dihydrobenzofuran (130 mg, 0.79 mmol) and Preparation 1 (296 mg) were reacted to give Example 13 (51.66 mg) as a white solid.
[0245] MS (ESI): m / z 521.2 [M+H] +
[0246] 1 H NMR(400MHz,DMSO-d6)δ7.25(d,J=2.1Hz,1H),7.10–7.06(m,2H),6.93(d,J=8.1Hz,1H),6.76(s,1H) ,6.67(t,J=5.4Hz,1H),6.62(d,J=8.1Hz,1H),6.53(d,J=8.3Hz,1H),6.49(d,J=3.0Hz,2H),4.46(t,J =8.7Hz,2H),3.97(dd,J=16.4,7.5Hz,1H),3.85(dd,J=16.8,7.3Hz,1H),3.75(s,3H),3.72–3.66(m, 1H),3.10–3.00(m,4H),2.96–2.74(m,4H),2.56(d,J=3.2Hz,1H),2.39(s,3H),1.00(t,J=7.1Hz,3H).
[0247] Example 14
[0248] Example 14 was prepared in a manner similar to Example 8. 2-(Benzo[d][1,3]dioxol-5-yl]ethane-1-ethane-1-ol (300 mg, 1.81 mmol) and Preparation 1 (564 mg, 1.51 mmol) were reacted to give Example 14 (206.5 mg) as a white solid.
[0249] MS (ESI): m / z 523.2 [M+H] +
[0250] 1H NMR(400MHz, DMSO-d6))δ7.24(d,J=1.2Hz,1H),7.10–7.05(m,1H),6.79( s,1H),6.78–6.75(m,2H),6.74–6.65(m,2H),6.52–6.48(m,3H),5.93(s,2 H),4.01–3.95(m,1H),3.89–3.85(m,1H),3.88–3.74(m,4H),3.15–3.00(m ,2H),2.90–2.75(m,4H),2.39(s,3H),1.25(s,1H),1.00(t,J=7.2Hz,3H).
[0251] Example 15
[0252] Step a:
[0253] To a dry 250 mL three-necked flask, compound 15-1 (1.00 g, 5.15 mmol) and an anhydrous tetrahydrofuran solution (30 mL) were added sequentially. Borane (8.0 mL, 8.0 mmol, 1.0 M) in tetrahydrofuran (30 mL) was then added dropwise at 0°C. The mixture was then warmed to room temperature and stirred for 4 hours. After completion of the reaction, as monitored by thin-plate chromatography (TLC), the reaction mixture was concentrated under reduced pressure, ice-water (80 mL) was added, and extraction with ethyl acetate (60 mL x 2) was performed. The organic layers were combined, washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to yield 15-2 (780 mg, yellow oil).
[0254] LC-MS (ESI): m / z 163.0 [M-OH] + .
[0255] Step b:
[0256] Example 15 was prepared by a method similar to that of Example 8. 15-2 was reacted with 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-ylethane-1-ethane-1-ol (200 mg, 1.11 mmol) and Preparation 1 (349 mg, 0.93 mmol) to give Example 15 (100 mg) as an off-white solid.
[0257] MS (ESI): m / z 537.2 [M+H] +
[0258] 1H NMR (400MHz, CDCl3) δ7.19 (d, J=2.1Hz, 1H), 6.99 (dd, J=8.2, 2.5Hz, 1H), 6.76 (d, J=8 .2Hz,1H),6.72(d,J=2.0Hz,1H),6.68–6.61(m,3H),6.48(s,1H),6.36(s,1H),4.22( s,4H),4.06–3.90(m,2H),3.86(s,3H),3.57–3.47(m,1H),3.33–3.22(m,3H),3.04–2 .89(m,3H),2.64(d,J=15.4Hz,1H),2.48(s,3H),1.63(s,1H),1.12(t,J=7.2Hz,3H).
[0259] Example 16
[0260] Example 16 was prepared in a manner similar to Example 5. Starting material 2-(Benzo[b]thiophen-5-yl]ethan-1-ol (200 mg, 1.12 mmol) and Preparation 1 (350 mg) gave Example 16 (62.55 mg) as a white solid.
[0261] MS (ESI): m / z 535.2 [M+H] + .
[0262] 1 H NMR(400MHz, DMSO-d6)δ7.88(d,J=8.2Hz,1H),7.76–7.70(m,2H),7.37(d,J=5.5Hz,1H),7.27( d,J=8.4Hz,1H),7.24(d,J=1.9Hz,1H),7.09–7.06(m,1H),6.76(s,1H),6.67(t,J=5.2Hz,1H),6 .52(t,J=4.1Hz,2H),6.48(s,1H),4.11–4.06(m,1H),4.02–3.95(m,1H),3.75(s,3H),3.70(s, 1H),3.06(t,J=6.4Hz,4H),2.96–2.75(m,2H),2.56(s,1H),2.38(s,3H),1.00(t,J=7.1Hz,3H).
[0263] Example 17
[0264] Example 17 was prepared in a manner similar to Example 16. 2-(Benzofuran-5-yl)ethan-1-ol (150 mg, 0.926 mmol) and Preparation 1 (346 mg, 0.926 mmol) were reacted to give Example 17 (9.27 mg) as a white solid.
[0265] MS (ESI): m / z 519.2 [M+H] +
[0266] 1 H NMR (400MHz, DMSO-d6)) δ7.93(d,J=2.4Hz,1H),7.51(s,1H),7.46(d,J=8.4Hz,1H),7.24(d,J=2.4Hz,1H) ,7.20(dd,J=8.4,1.6Hz,1H),7.07(dd,J=8.0,1.5Hz,1H),6.87(dd,J=2.4,1.2Hz,1H),6.76(s,1H),6.67( t,J=5.4Hz,1H),6.54–6.51(m,2H),6.48(s,1H),4.10–4.04(m,1H),3.98–3.91(m,1H),3.75(s,3H),3.74– 3.68(m,1H),3.12–3.00(m,4H),2.96–2.74(m,2H),2.56–2.51(m,1H),2.38(s,3H),1.00(t,J=7.2Hz,3H).
[0267] Example 18
[0268] Step a:
[0269] 5-Bromo-1,3-dihydro-2H-indene-2-one 18-1 (900.0 mg, 0.476 mmol) was dissolved in anhydrous dichloromethane (20.00 ml), diethylaminosulfur trifluoride (DAST) (1.414 g, 0.976 mmol) was added under nitrogen protection at -60 ° C, and the mixture was stirred to room temperature under nitrogen atmosphere for 16 hours. After the reaction was completed, water (20 ml) was added to the reaction mixture. Then, the mixture was extracted with dichloromethane (5 ml x 2). The organic phase was washed with saturated brine (20 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain 18-2 (501 mg) as a colorless oily compound.
[0270] 1H NMR (400MHz, CDCl3) δ7.37-7.35 (m, 2H), 7.09 (d, J = 8.8Hz, 1H), 3.45-3.33 (m, 4H).
[0271] Step b:
[0272] Under nitrogen at room temperature, 18-2 (200 mg, 0.86 mmol) was added to 1,4-dioxane (5 mL). Vinyloxymethyl-benzene 18-3 (121 mg, 0.49 mmol), tetrakis(triphenylphosphine)palladium (50 mg, 0.024 mmol), and potassium carbonate (119 mg, 0.47 mmol) were then added. The mixture was stirred at 100°C under nitrogen for 10 hours. After the reaction, the mixture was cooled, filtered, and concentrated under reduced pressure. The crude product was purified on a silica gel column (eluted with petroleum ether:ethyl acetate = 20:1) to afford 18-4 (70 mg) as a colorless oil.
[0273] 1 H NMR (400MHz, CDCl3) δ7.40-7.35(m,5H),7.12-7.06(m,3H),7.05(d,J=12.8Hz,1H),5.94(d,J=12.8Hz,1H),4.89(s,2H),3.38(t,J=14.4Hz,4H).
[0274] Step c:
[0275] 18-4 (60 mg, 0.21 mmol) was dissolved in methanol (5 mL), and 10% Pd / C (10 mg) was added sequentially under nitrogen. The resulting mixture was stirred under hydrogen for 12 hours. The reaction mixture was cooled to room temperature, filtered through a pad of Celite, and the filter cake was washed with methanol (2 x 5 mL). The filtrate was concentrated under reduced pressure to obtain 18-5 (40 mg) as a colorless yellow oil.
[0276] 1 H NMR (400MHz, CDCl3) δ7.17-7.15(m,1H),7.11-7.09(m,2H),3.84(t,J=6.4Hz,2H),3.43–3.36(m,4H),2.84(t,J=6.4Hz,2H), 1.75-1.65(br.s,1H).
[0277] Step d:
[0278] To a stirred mixture of 18-5 (3 mg, 0.015 mmol) and triethylamine (1.5 mg, 0.03 mmol) in DCM (5 mL) was added MsCl (3 mg, 0.03 mmol) at room temperature. The resulting mixture was stirred for 2 h and concentrated to give a crude white solid 18-6 (5 mg), which was used directly in the next step without further purification.
[0279] Step e:
[0280] A mixture of the crude product 18-6 (5 mg, 0.018 mmol), Preparation 1 (6 mg, 0.016 mmol), and cesium carbonate (18 mg, 0.054 mmol) in DMF (2 mL) was stirred at 80°C for 16 h. After completion of the reaction, the mixture was cooled and concentrated under reduced pressure to afford the crude product, which was purified by reverse-phase preparative HPLC to afford Example 18 (3 mg) as a white solid.
[0281] MS (ESI): m / z 555.0 [M+H] +
[0282] 1 H NMR(400MHz,CD3OD-d4)δ7.21(d,J=2.0Hz,1H),7.12–7.07(m,3H),7.02–7.00 (m,1H),6.77(s,1H),6.58(d,J=8.4Hz,1H),6.46(s,1H),6.43(s,1H),4.10–4 .01(m,2H),3.80(s,3H),3.75–3.70(m,1H),3.37–3.30(m,3H),3.24–2.94(m, 4H),2.96–2.72(m,3H),2.62–2.58(m,1H),2.43(s,3H),1.10(t,J=6.8Hz,3H).
[0283] 19 F NMR (376MHz, CD3OD-d4): δ-95.80ppm.
[0284] Example 19 and Example 20
[0285] Step a:
[0286] Under nitrogen protection, PdCl2(dppf) (360 mg, 0.49 mmol) was added to a solution of methyl 2-bromo-4-iodobenzoate 19-1 (2.5 g, 7.33 mmol), boronate ester 19-2 (1.52 g, 7.7 mmol) and K2CO3 (2.03 g, 14.66 mmol) in 1,4-dioxane (25 ml) and H2O (2.5 ml). The mixture was then heated at 100°C overnight. The reaction was stopped and filtered after cooling, and the mixture was concentrated under reduced pressure to obtain a crude product, which was further purified by silica gel column (PE / EA = 20% eluent) to obtain (E)-methyl 2-bromo-4-(2-ethoxyvinyl)benzoate 19-3 (1.668 g) as a yellow oil.
[0287] MS (ESI): m / z 285.0 [M+H] + .
[0288] Step b:
[0289] At room temperature, 5-6 drops of water were added to a solution of (E)-2-bromo-4-(2-ethoxyvinyl)benzoic acid methyl ester 19-3 (1.6 g, 5.63 mmol) in hydrochloric acid (4N in EtOAc, 15 ml). The mixture was then stirred overnight at room temperature. LCMS monitoring indicated that the reaction was complete. After the reaction was stopped, the mixture was directly concentrated under reduced pressure at low temperatures to obtain the crude product, 2-bromo-4-(2-oxyethyl)benzoic acid methyl ester 19-4, as a yellow oil. 19-4 was used directly in the next step.
[0290] MS (ESI): m / z 257.0 [M+H] + .
[0291] Step c:
[0292] The above crude product 19-4 was dissolved in THF (10 ml), NaBH4 (1.3 g) was added, and then stirred at room temperature for 2 hours. After the reaction was completed, water (15 ml) was added and extracted with ethyl acetate (150 ml * 3), washed with brine and dried. Pressure concentration gave a crude product, which was then further purified by column chromatography (PE / EtOAc = 50% eluent) to give methyl 2-bromo-4-(2-hydroxyethyl)benzoate 19-5 (695 mg, two-step yield 48%) as a yellow oil.
[0293] MS (ESI): m / z 259.0 [M+H] + .
[0294] Step d:
[0295] TFA solution (30 ml) was added dropwise to a mixture of 4-(2-aminoethyl)-2-methoxyphenol 19-6 (2.5 g, 14.97 mmol) and 2,4-dimethylbenzaldehyde 19-7 (2.5 ml, 17.96 mmol) at 0°C. The reaction mixture was stirred at 100°C for 24 hours. After completion of the reaction, the mixture was quenched with an appropriate amount of water, and the pH of the mixture was adjusted to 10 by adding aqueous ammonia solution. The mixture was extracted three times with ethyl acetate (150 ml x 3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to afford 1-(2,4-dimethylphenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 19-8 (1.9 g) as a brown solid.
[0296] MS (ESI): m / z 284.0 [M+H] + .
[0297] Step e:
[0298] To a solution of oxazol-4-ylcarboxamide hydrochloride 19-9 (464 mg, 3.44 mmol) in DMF (2 mL) at room temperature was added triethylamine (1 g, 9.92 mmol). The mixture was then stirred at this temperature for 10 minutes. CDI (382 mg, 2.36 mmol) was then added and stirring continued for 1 hour. 1-(2,4-dimethylphenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 19-8 (350 mg, 1.24 mmol) (pre-dissolved in 5 mL of DMF) was then added to the solution and stirring continued overnight at room temperature. The reaction was monitored by LCMS. After the reaction, 20 ml of water was added and the mixture was extracted with EtOAc (100 ml * 3), washed with NH4Cl (aq.) and brine, dried and filtered, and concentrated under reduced pressure to obtain a crude product, which was further redissolved in EtOAc (5 ml), and the solid was collected and dried to give 1-(2,4-dimethylphenyl)-7-hydroxy-6-methoxy-N-(oxazol-4-ylmethyl)-3,4-dihydroisoquinoline-2(1H)-carboxamide 19-10 (376 mg) as a yellow solid.
[0299] MS (ESI): m / z 408.0 [M+H] + .
[0300] Step f:
[0301] Under nitrogen, a mixture of 1-(2,4-dimethylphenyl)-7-hydroxy-6-methoxy-N-(oxazol-4-ylmethyl)-3,4-dihydroisoquinoline-2(1H)-carboxamide 19-10 (30 mg, 0.074 mmol), methyl 2-bromo-4-(2-hydroxyethyl)benzoate 19-5 (29 mg, 0.011 mmol), PPh3 (29 mg, 0.11 mmol), and toluene (2 ml) was refluxed at 110°C for 10 minutes. After the reaction mixture became clear, DIAD (22 mg, 0.11 mmol) (pre-dissolved in 1 ml of toluene) was slowly added dropwise at the same temperature. The mixture was then stirred at 110°C overnight. LCMS indicated the formation of the desired product. Some 19-10 remained. After the reaction was stopped and cooled, it was concentrated under reduced pressure and dried to give the crude product, which was further purified by basic Pre-HPLC under basic conditions to give methyl 2-bromo-4-(2-((1-(2,4-dimethylphenyl)-6-methoxy-2-((oxazol-4-ylmethyl)carbamoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)ethyl)benzoate Example 19 (10 mg) as a white solid.
[0302] MS (ESI): m / z 648.0 [M+H] + .
[0303] 1H NMR(400MHz,MeOD)δ8.10(s,1H),7.65(dd,J=7.8,4.8Hz,3H),7.30(dd,J=8.0,1.5Hz,1H),7. 00(s,1H),6.82(d,J=7.5Hz,1H),6.76(s,1H),6.47(dd,J=14.8,6.1Hz,3H),4.29(q,J=16.0H z,2H),4.15–4.03(m,2H),3.88(s,3H),3.81(s,3H),3.75(dd,J=14.5,5.9Hz,1H),3.24–3.16 (m,1H),2.97(dt,J=12.8,6.1Hz,3H),2.61(dd,J=16.6,3.4Hz,1H),2.37(s,3H),2.24(s,3H).
[0304] MS (ESI): m / z 648.0 [M+H] + .
[0305] Step g:
[0306] To a mixture of Example 19 (60 mg, 0.09 mmol, 1.0 eq) in tetrahydrofuran was added LiAlH4 (4 mg, 0.09 mmol, 1 eq) under nitrogen at 0°C. The mixture was stirred at 0°C for 1 hour. After the reaction was completed, the LiAlH4 reaction mixture was quenched with water (0.5 ml), 15% sodium hydroxide solution (0.5 ml), and water (1 ml) under cooling at 0°C. After stirring for 30 minutes, it was extracted with ethyl acetate (3 x 10 ml). The combined organic layers were washed with saturated brine (10 ml), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. Purification by Pre-HPLC gave Example 20 (3.35 mg) as a yellow solid.
[0307] MS (ESI): m / z 620.0 [M+H] + .
[0308] 1H NMR (400MHz, DMSO) δ8.27(s,1H),7.74(s,1H),7.50(s,1H),7.40(d,J=7.9Hz,1H),7.26(d,J=8.4Hz,1H),7. 11(t,J=5.5Hz,1H),6.98(s,1H),6.81(d,J=7.9Hz,1H),6.75(s,1H),6.47(s,2H),6.41(d,J=7.8Hz,1H),5.3 3(t,J=5.6Hz,1H),4.46(d,J=5.6Hz,2H),4.16(qd,J=15.6,5.5Hz,2H),4.03(dd,J=16.1,6.6Hz,1H),3.90( dd,J=16.3,7.0Hz,1H),3.75(s,4H),3.29(s,1H),3.03–2.77(m,4H),2.34(s,3H),2.20(s,3H),0.00(s,3H).
[0309] Test Example 1: Cell proliferation inhibition experiment
[0310] Four commercially available tumor cell lines, PANC-1 (G12D), H358 (G12C), A549 (G12S), and HCT116 (G13D), were selected for cell proliferation inhibition experiments. Cells were cultured in DMEM, DMEM, F12K, McCoy's 5A, RPMI-1640, and EMEM (Gibco, ThermoFisher) supplemented with 10% fetal bovine serum, respectively, in a 37°C, 5% CO2 incubator. Cells were observed under an inverted microscope to observe adherent growth and were subcultured when the cell number reached an appropriate level.
[0311] PANC-1, H358, A549, and HCT116 cells in the logarithmic growth phase were seeded at an appropriate cell density in 96-well cell culture plates (Corning). After incubation at 37°C in a cell culture incubator containing 5% CO2 for 24 hours, 10 μL of the test compound or positive drug was added to each well. A positive control group (100% inhibition well) and a negative control group (0% inhibition well) were also set up. Two replicates were set for each drug concentration, and six replicates were set for the positive and negative control groups. After further incubation for 5 days, the AlamarBlue assay was performed.
[0312] AlamarBlue test operation: add 10 μL AlamarBlue reagent (ThermoFisher) to each well, incubate for 1-4 hours, shake for 1-2 minutes, measure the fluorescence value with MD microplate reader at EX: 560nm, EM: 590nm wavelength, record the results, and calculate the drug inhibition rate (%) = (A 0%抑制 -A 药物 ) / (A 0%抑制 -A 100%抑制 ) × 100%. Dose-response curves were then plotted using MATILAB software using nonlinear regression (often using a four-parameter logistic model) to obtain compound IC50 values and other relevant parameters. The inhibitory activity (IC50, μM) of the test compounds against six commercial tumor cell lines (PANC-1, H358, A549, and HCT116) is shown in Table 2 below.
[0313] Compound biological activity data
[0314] Table 1: Cell proliferation inhibition (IC 50 :μM)
[0315] Test Example 2: KRAS Protein Interaction (PPI) Experiment
[0316] In this experiment, homogeneous time-resolved fluorescence (HTRF) was used to detect the inhibitory activity of small molecule compounds on the interaction between GTP-activated KRAS and the downstream RAF1 protein. A purified Tag1-RAF1 protein stock solution was diluted 100-fold with TR-FRET buffer. Similarly, a mixture of purified Tag2-KRAS protein and GTP was diluted 100-fold with TR-FRET buffer to ensure a final GTP concentration of 10 μM. The working concentrations of these proteins were optimized to ensure maximal signal generation. Test compounds were serially diluted in DMSO to generate a range of compound concentrations, with a final DMSO concentration of 0.5%. To a 384-well white shallow plate (PerkinElmer), 4 μL of GTP-KRAS protein, 4 μL of RAF1 protein, and 2 μL of compound working solution were added. Appropriate controls (no compound wells and positive compound wells) were also included in the 384-well plate. GTP-KRAS protein, RAF1 protein and compound were pre-incubated in 384-well plate for 15 minutes, and then 10 μL Anti-Tag1-Eu diluted in HTRF detection buffer was added. 3+ The reaction was initiated with a mixture of the labeled antibody and Anti-Tag2-XL665. The plates were sealed and incubated at 4°C in the dark for 2 hours. The TR-FRET signal was measured using an EnVision microplate reader (PerkinElmer) (excitation wavelength: 320 nm, emission wavelengths: 615 nm and 665 nm). The fluorescence signal ratio (RLU) was calculated as (665 nm signal / 615 nm signal) x 10 4 The compound % inhibition rate is calculated by setting the 0% inhibition rate well and the 100% inhibition rate well signals, which are the maximum signal reaction well (well without compound, DMSO control well) and the minimum signal reaction well (well without KRAS protein), respectively. The compound inhibition rate IR (%) formula = (RLU 0%抑制 -RLU 化合物 ) / (RLU 0%抑制 -RLU 100%抑制 ) x 100%, and the IC50 value was calculated by fitting the compound gradient dilution concentration and the corresponding inhibition rate using the 4-parameter logistic model. 50 , μM) and the results are shown in Table 1 below.
[0317] Compound biological activity data
[0318] Table 2 KRRAS G12D protein inhibitory activity (IC 50 :μM)
[0319] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, in, *The carbon atom marked is a chiral center, and each chiral center can optionally be in the R configuration or the S configuration; R1 is selected from the group consisting of: wherein A, B, C and D are each independently selected from the group consisting of CH, CF, C(OMe), CMe or N; Each R'1 is independently selected from the group consisting of halogen, OH, OCH2CH2NR a R b , SH, NH2, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkylhydroxyl, S (C1-C6 alkyl), allyl, vinyl, aryl (including monocyclic or condensed ring aryl), heteroaryl (including monocyclic or condensed ring heteroaryl), COR a 、CONH2、CONR a R b 、NHR a , 3-7 membered cycloalkyl, 3-7 membered heterocyclyl, (C1-C4 alkyl) 3-7 membered heterocyclyl; wherein, when A, B, C or D is CH, each R'1 may be optionally located on A, B, C or D, and in this case, the H atom on A, B, C or D is replaced by R'1; R a Selected from the group consisting of H, C1-C5 alkyl; R b Selected from the group consisting of H, C1-C5 alkyl, or C1-C5 haloalkyl; m is 0, 1, 2, 3, 4 or 5; R2 is selected from the following group: halogen, OH, NH2, NHR a , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, allyl, vinyl, OCD3, OR c , 3-7 membered cycloalkyl, 3-7 membered heterocyclic group, (C1-C4 alkyl) 3-7 membered heterocyclic group, SR c , B(OH)2, or a heterocycle selected from the group consisting of: Preferably, R2 is selected from the group consisting of OMe, OCD3; R c is a C1-C6 alkyl group or an allyl group; L is selected from the group consisting of a single bond, O, S, NH, N(C1-C6 alkyl), CH2, CF2; Q is selected from the group consisting of a single bond, (CH2) p ; wherein p is 1, 2, 3 or 4; R3 is selected from the following group: H, Each R3' can be independently located at any position on the ring and is independently selected from the following group: halogen, OH, SH, NH2, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkylhydroxy, S(C1-C6 alkyl), allyl, vinyl, aryl (including monocyclic or condensed ring aryl), heteroaryl (including monocyclic or condensed ring heteroaryl), piperidinyl, morpholinyl; n is 0, 1, 2 or 3; X is selected from the group consisting of O, N, NH, S, CH, CH2, CF2, CFH, NR a ; Y is selected from the group consisting of NH, CH, CO, CH2, CF2, CR a , OR a 、S(C1-C6 alkyl), C(NR a R b ), C(aryl), C(heteroaryl), C(3-8 membered cycloalkyl), C(3-8 membered heterocyclyl); Z, E and F are each independently selected from the group consisting of O, N, NH, S, CH, CH2, CF2, CFH, NR a ; R4 is selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylhydroxy, C1-C6 alkoxy, C2-C6 acyl, allyl, cycloalkyl, heterocyclyl, propargyl, C(O)NH2, CH2(aryl), CH2(heteroaryl), C(O)NH(C1-C6 alkyl), C(O)NH(aryl), C(O)NH(heteroaryl), C(O)NHCH2(aryl), C(O)NHCH2(heteroaryl), C(S)NH2, C(S)NH(C1-C6 alkyl), C(S)NH(aryl), C(S)NH(heteroaryl), C(S)NHCH2(aryl), C(S)NHCH2(heteroaryl), aryl, heteroaryl; R5 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, and cycloalkyl; preferably, R5 is selected from the group consisting of methyl, fluoromethyl, ethyl, fluoroethyl, deuterated methyl, isopropyl, and cyclopropyl; R6 or R7 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C2-C6 alkenyl, CH2O(C1-C5 alkyl); When R5 is H, R3 is selected from the following group: In the above formulas, unless otherwise specified, the aryl group is C6-C 14 Aryl, heterocyclic group is 3-12 membered heterocyclic group, heteroaryl is 5-14 membered heteroaryl (such as 5-6 membered heteroaryl or benzo 5-6 membered heteroaryl), cycloalkyl is C3-C 12 Cycloalkyl (e.g., C3-C6 cycloalkyl or C3-C8 cycloalkyl); the heterocyclic group or heteroaryl group includes 1-3 heteroatoms selected from the group consisting of N, S, O, P, or B; and unless otherwise specified, the vinyl, allyl, propargyl, aryl, heteroaryl, cycloalkyl, and heterocyclic group may optionally have 1-3 substituents selected from the group consisting of halogen, deuterium atom, and C1-C6 alkyl; The heterocyclic group includes saturated or partially unsaturated nitrogen, oxygen or sulfur heterocycles; It is a single bond or a double bond.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: L is selected from the following group: O, S, NH, CF2; Q is selected from the following group: (CH2) p ; where p is 1, 2 or 3.
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R4 is selected from the following group: C(O)NH(C1-C6 alkyl), C(O)NH(aryl), C(O)NH(heteroaryl), C(O)NHCH2(aryl), C(O)NHCH2(heteroaryl), C(S)NH2, C(S)NH(C1-C6 alkyl), C(S)NH(aryl), C(S)NH(heteroaryl), C(S)NHCH2(aryl), C(S)NHCH2(heteroaryl).
4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: R2 is selected from the following group: C1-C6 alkoxy, C1-C6 haloalkoxy, OCD3, R5 is selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, and cycloalkyl; preferably, R5 is selected from the group consisting of methyl, fluoromethyl, ethyl, fluoroethyl, deuterated methyl, isopropyl, and cyclopropyl; R6 or R7 are each independently selected from the group consisting of hydrogen, deuterium, halogen, and C1-C6 alkyl.
5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The R1 is selected from the following group:
6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: The R3 is selected from the following group: wherein each R3′ is independently selected from the group consisting of halogen, OH, SH, NH2, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkylhydroxy, S(C1-C6 alkyl), allyl, vinyl, aryl (including monocyclic or condensed ring aryl), heteroaryl (including monocyclic or condensed ring heteroaryl), piperidinyl, and morpholinyl; X is selected from the group consisting of O, N, NH, S, CH, CH2, CF2, CFH, NR a ; Y is selected from the group consisting of NH, CH, CO, CH2, CF2, CR a , OR a 、S(C1-C6 alkyl), C(NR a R b ), C(aryl), C(heteroaryl), C(3-8 membered cycloalkyl), C(3-8 membered heterocyclyl); Z is selected from the following group: O, N, NH, S, CH, CH2, CF2, CFH, NR a ; E and F are each independently selected from the group consisting of O, N, NH or S.
7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: The R3 is selected from the following group: Or the R3 is wherein one of X and Z is selected from the group consisting of O, S, NH, and CH2; and the other is selected from the group consisting of CH and N; Y is selected from the group consisting of NH, CH, CO, CH2, CF2, CR a , OR a 、S(C1-C6 alkyl), C(NR a R b ), C(aryl), C(heteroaryl), or a group selected from the group consisting of:
8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The compound of formula I has a structure shown in the following formula (II), (III), (IV) or (IV-A): in: R2 is selected from the following group: halogen, OH, NH2, NHR a , C1-C6 alkyl, C1-C6 haloalkyl, allyl, vinyl, OCD3, OR c , 3-7 membered cycloalkyl, 3-7 membered heterocyclic group, (C1-C4 alkyl) 3-7 membered heterocyclic group, SR c ; Preferably, R2 is selected from the following group: OMe, OCD3.
9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The compound of formula I has a structure as shown in the following formula (II-A), (V), (VI) or (VI-A): Preferably, in the formula (II-A), (V), (VI) or (VI-A), each R3' is independently selected from the following group: halogen, OH, SH, NH2, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkylhydroxyl, S(C1-C6 alkyl), allyl, vinyl.
10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein: The compound of formula I is selected from the following group: Preferably, the compound of formula I is selected from the following group:
11. The compound and precursor compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that: The compound of formula I is selected from the following group:
12. The compound or precursor compound thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof according to claim 1, characterized in that: The compound of formula I is selected from the following group:
13. The use of the compound according to any one of claims 1 to 12, characterized in that Use of a drug for treating a disease associated with the activity or expression of a KRAS mutant; preferably, the disease associated with the activity or expression of a KRAS mutant is a tumor, preferably a tumor selected from the group consisting of sarcoma, myxoma, rhabdomyomas, fibromas, lipomas, teratomas, bronchial cancer, lung cancer, bronchial adenoma, lymphoma, chondroma, hamartoma, mesothelioma, esophageal cancer, gastric cancer, pancreatic cancer, small intestine cancer, colorectal cancer, genitourinary tract tumors, kidney cancer, bladder cancer, urethral cancer, prostate, testicular cancer, liver cancer, bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, gallbladder cancer, ampullary cancer, bile duct cancer, bone cancer, brain cancer, uterine cancer, vaginal cancer, hematologic tumors, skin cancer, and breast cancer.
14. A pharmaceutical composition comprising: (i) a therapeutically effective amount of a compound of formula I according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable carrier.
